Molecular pathogenesis of human hepatocellular carcinoma

Nature Genetics

Volumn 31, Issue 4, 2002, Pages 339-346

  Thorgeirsson, Snorri S ^a   Grisham, Joe W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

CHROMOSOME STRUCTURE; GENE DISRUPTION; GENE STRUCTURE; GENOMICS; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MICROSATELLITE INSTABILITY; MITOGENICITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TELOMERE;

CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; PRECANCEROUS CONDITIONS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0036699940     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng0802-339     Document Type: Review

References (96)

1. Ferlay, J., Bray, F., Pisani, P. & Parkin, D.M.J. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0., IARC Cancer Base No. 5 (Lyon, IARC Press, 2001).
2. Parkin, D.M., Bray, F.I. & Devesa, S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-S66 (2001).
3. Grisham, J.W. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In The Molecular Basis of Human Cancer (eds Coleman, W.B. & Tsongalis, G.J.) 269-346 (Humana Press, Totowa, New Jersey, 2001).
4. Bosch, F.X., Ribes, J. & Borràs, J. Epidemiology of primary liver cancer. Semin. Liver Dis. 19, 271-285 (1999).
5. Buendia, M.A. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 10, 185-200 (2000).
6. Bréchot, C. Molecular mechanisms of hepatitis B and C related to liver carcinogenesis. Hepatogastroenterology 45 (Suppl 3), 1189-1196 (1998).
7. Diao, J., Garces, R. & Richardson, C.D. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis (Survey). Cytokine Growth Factor Rev. 12, 189-205 (2001).
8. Smela, M.E., Currier, S.S., Bailey, E.A. & Essigmann, J.M. The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis. Carcinogenesis 22, 535-545 (2001).
9. Tong, M.J., El-Farra, N.S., Reikes, A.R. & Co, R.L. Clinical outcomes after transfusion-associated hepatitis C. New Engl. J. Med. 332, 1463-1466 (1995).
10. Takano, S., Yokosuka, O., Imazeki, F., Tagawa, M. & Omata, M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21, 650-655 (1995).
11. Chu, C.M. Natural history of chronic hepatitis B infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 15 (Suppl) E25-E30 (2000).
12. Oka, H. et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12, 680-687 (1990).
13. Ikeda, K. et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18, 47-53 (1993).
14. Kato, Y. et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 74, 2234-2238 (1994).
15. del Olmo, J.A. et al. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J. Cancer Res. Clin. Oncol. 124, 560-564 (1998).
16. Chiaramonte, M. et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85, 2132-2137 (1999).
17. Takayama, T. et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 336, 1150-1153 (1990).
18. Seki S. et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin. Cancer Res. 6, 3469-3473 (2000).
19. Kawakita, N. et al. Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde. Am. J. Pathol. 140, 513-520 (1992).
20. Schwienbacher, C. et al. Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinoma. Proc. Natl Acad. Sci. USA 97, 5445-5449 (2000).
21. Soini, Y., Virkajärvi, N., Lehto, V.P. & Pääkkö, P. Hepatocellular carcinoma with a high proliferative index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br. J. Cancer 73, 1025-1030 (1996).
22. Theise, N.D. et al. Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 16, 134-139 (1996).
23. Paradis, V., Laurendeau. I., Vidaud, M. & Bedossa, P. Clonal analysis of macronodules in cirrhosis. Hepatology 28, 953-958 (1998).
24. Ochai, T., Urata, Y., Yamano, T., Yamagishi, H. & Ashihara, T. Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. Hepatology 31, 615-621 (2000).
25. Paradis, V. et al. Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay. Lab. Invest. 80, 1553-1559 (2000).
26. Okuda, T. et al. Clonal analysis of hepatocellular carcinoma and dysplastic nodule by methylation pattern of X-chromosome-linked human androgen receptor gene. Cancer Lett. 164, 91-96 (2001).
27. Kitamoto, M. & Ide, T. Telomerase activity in precancerous hepatic nodules. Cancer 85, 245-248 (1999).
28. Takaishi, H. et al. Precancerous hepatic nodules had significant levels of telomerase activity determined by sensitive quantitation using hybridization protection assay. Cancer 88, 312-317 (2000).
29. Toshikuni, N. et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br. J. Cancer 82, 833-837 (2000).
30. Liu, Y.W., Chang, K.J. & Liu, Y.C. DNA hypomethylation of proliferating cell nuclear antigen gene in human hepatocellular carcinoma is not due to cell proliferation. Cancer Lett. 70, 189-196 (1993).
31. Shen, L. et al. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepatogastroenterology 45, 1753-1759 (1998).
32. Kanai, Y. et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 29, 703-709 (1999).
33. Nagai, H. et al. A novel sperm-specific hypomethylation sequence is a demethylation hotspot in human hepatocellular carcinoma. Gene 237, 15-20 (1999).
34. Kanai, Y., Ushijima, S., Tsuda, H., Sakamoto, M. & Hirohashi, S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett. 148, 73-80 (2000).
35. JinBaek, M. et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89, 60-68 (2000).
36. Kondo, Y. et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 32, 970-979 (2000).
37. Takai, D., Yagi, Y., Habib, N., Sugimura, T. & Ushijima, T. Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn. J. Clin. Oncol. 30, 306-309 (2000).
38. Tchou, J.C. et al. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinoma. Int. J. Oncol. 16, 663-676 (2000).
39. INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48, 372-377 (2001).
40. Lin, C.H. et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 61,4238-4243 (2001).
41. Saito, Y. et al. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33, 561-568 (2001).
42. Karachristos, A. et al. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol. Cell Biol. Res, Commun. 2, 155-161 (1999).
43. Kawai, H. et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 31, 1246-1250 (2000).
44. Maggioni, M. et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology 32, 942-946 (2000).
45. Park, Y.M. et al. Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea. Hepatol. Res. 17, 102-111 (2000).
46. Piao, Z., Kim, H., Malkhosyan, S. & Park, C. Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas. Int. J. Oncol. 17, 507-512 (2000).
47. Roncalli, M. et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 31, 846-850 (2000).
48. Saeki, A. et al. Lack of frameshift mutations at coding mononucleotide repeats in hepatocellular carcinoma in Japanese patients. Cancer 88, 1025-1029 (2000).
49. Sun, M. et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 33, 1415-1424 (2001).
50. INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma. Anticancer Res. 20, 1621-1626 (2000).
51. Okabe, H. et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 31, 1073-1079 (2000).
52. Chen, Y.J. et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119, 431-440 (2000).
53. Guan, X.Y. et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 29, 110-116 (2000).
54. Marchio, A. et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 19, 3733-3738 (2000).
55. Tornillo, L. et al. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. J. Pathol. 192, 307-312 (2000).
56. Wong, N. et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin. Cancer Res. 6, 4000-4009 (2000).
57. Zondervan, RE. et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J. Pathol. 192, 207-215 (2000).
58. Balsara, B.R. et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30, 245-253 (2001).
59. Rao, U.N. et al. Comparative genomic hybridization of hepatocellular carcinoma: correlation with fluorescence in situ hybridization in paraffin-embedded tissue. Mol. Diagn. 6, 27-37 (2001).
60. Wilkens, L. et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J. Pathol. 193, 476-482 (2001).
61. Laes, J. et al. Alterations in P19ARF in rodent hepatoma cell lines but not in human primary liver cancer. Cancer Genet. Cytogenet. 117, 118-124 (2000).
62. Wong, N. et al. A comprehensive karyotype study of human hepatocellular carcinoma by spectral karyotyping. Hepatology 32, 1060-1068 (2000).
63. Strauss, B.S. Frameshift mutation, microsatellites, and mismatch repair. Mutat. Res. 437, 195-203 (1999).
64. Loeb, L.A. A mutator phenotype in cancer. Cancer Res. 61, 3230-3239 (2001).
65. Stewart, S.A. & Weinberg, R.A. Telomerase and human tumorigenesis. Semin. Cancer Biol. 10, 399-406 (2000).
66. Kane, J.M. III et al. Chronic hepatitis C virus infection in humans: induction of hepatic nitric oxide synthase and proposed mechanisms for carcinogenesis. J. Surg. Res. 69, 321-324 (1997).
67. Hussain, S.P. et al. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc. Natl Acad. Sci. USA 97, 12770-12775 (2000).
68. Nishikawa, M. et al. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res. 61, 1843-1845 (2001).
69. Yamamoto, H. et al. Infrequent widespread microsatellite instability in hepatocellular carcinoma and non-HCC tissues. Oncology Rep. 7, 725-729 (2000).
70. Shi, C.Y. et al. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br. J. Cancer 72, 146-149 (1995).
71. Terris, B. et al. Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 18, 6583-6588 (1999).
72. Hsu, H.C. et al. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 157, 763-770 (2000).
73. Satoh, S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24, 245-250 (2000).
74. Stern, M.C. et al. Hepatitis B, aflatoxin B1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol. Biomarkers Prev. 10, 617-625 (2001).
75. Mao, T.L., Chu, J.S., Jeng, Y.M., Lai, P.L. & Hsu, H.C. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J. Pathol. 193, 95-101 (2001).
76. Wilkens, L., Bredt, M., Flemming, P., Klempnauer, J. & Heinrich Kreipe, H. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J. PathoL 192, 43-51 (2000).
77. van Oijen, M.G. & Slootweg, P.J. Oral field cancerization: carcinogen-induced independent events or micrometastastic deposits? Cancer Epidemiol. Biomarkers Prev. 9, 249-256 (2000).
78. Ng, I.O., Liang, Z.D., Cao, L. & Lee, T.K. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 60, 6581-6584 (2000).
79. Emmert-Buck, M.R. et al. Laser capture microdissection. Science 274, 998-1001 (1996).
80. Tao, L.C. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 68, 341-347 (1991).
81. Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48-56 (2000).
82. Hsu, H.C., Cheng, W. & Lai, P.L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 57, 5179-5184 (1997).
83. Lau, W.Y. et al. Differential gene expression of hepatocellular carcinoma using cDNA microarray analysis. Oncol. Res. 12, 59-69 (2000).
84. Honda, M., Kaneko, S., Kawai, H., Shirota, Y. & Kobayashi, K. Differential gene expression between chronic hepatitis 8 and C hepatic lesion. Gastroenterology 120, 955-966 (2001).
85. Lu, T. et al. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol. Sci. 59, 185-192 (2001).
86. Okabe, H. et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61, 2129-2137 (2001).
87. Shirota, Y., Kaneko, S., Honda, M., Kawai, H.F. & Kobayashi, K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 33, 832-840 (2001).
88. Xu, L. et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 61, 3176-3181 (2001).
89. Yamashita, T. et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 282, 647-654 (2001).
90. Pollack, J.R. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 23, 41-46 (1999).
91. Lindblad-Toh, K, et al. Loss of heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat. Biotechnol. 18, 1001-1005 (2000).
92. Risch, N.J. Searching for genetic determinants in the new millennium. Nature 405, 847-856 (2000).
93. Grisham, J.W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 18, 59-81 (1997).
94. Kemp, C.J. Comparative hepatocellular cancer genetics. Am. J. Pathol. 154, 975-977 (1999).
95. Fausto, N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease, Semin. Liver Dis. 19, 243-252 (1999).
96. Thorgeirsson, S.S., Factor, V.M. & Snyderwine, E.G. Transgenic mouse models in carcinogenesis research and testing. Toxicol. Lett. 112-113, 553-555 (2000).